Viking Therapeutics (VKTX) Q2 FY26 earnings call

Viking Therapeutics advanced its obesity pipeline in Q2 FY26, with its lead compound VK2735 progressing in both subcutaneous and oral Phase III programs, and a novel dual amylin/calcitonin receptor agonist, VK3019, entering Phase I. The company is also exploring maintenance dosing strategies for VK2735 and has strengthened its leadership team, while maintaining a strong cash position to fund ongoing and future initiatives.